{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:01:03Z","timestamp":1789236063082,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014571","name":"Alvin J. Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jtct.2022.05.020","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:17Z","timestamp":1653004817000},"page":"510.e1-510.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-7739","authenticated-orcid":false,"given":"Lawrence Wayne","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Yn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-1623","authenticated-orcid":false,"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1537-7145","authenticated-orcid":false,"given":"Marissa","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-4820","authenticated-orcid":false,"given":"Mallory","family":"Crain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-4155","authenticated-orcid":false,"given":"Ramzi","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-3518","authenticated-orcid":false,"given":"Camille","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-1715","authenticated-orcid":false,"given":"Keith","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.05.020_bib0001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5500\/wjt.v5.i4.287","article-title":"Cytomegalovirus infection in the bone marrow transplant patient","volume":"5","author":"Bhat","year":"2015","journal-title":"World J Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2022.05.020_bib0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/jinf.2001.0949","article-title":"Clinical aspects and management of cytomegalovirus infection","volume":"44","author":"Sissons","year":"2002","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2022.05.020_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.05.020_bib0006","doi-asserted-by":"crossref","first-page":"e13619","DOI":"10.1111\/tid.13619","article-title":"Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis","volume":"23","author":"Chen","year":"2021","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.jtct.2022.05.020_bib0007","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"15-suppl","key":"10.1016\/j.jtct.2022.05.020_bib0008","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1200\/JCO.2021.39.15_suppl.7004","article-title":"Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease","volume":"39","author":"Wolfe","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.020_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.jtct.2022.05.020_bib0011","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1002\/sim.2864","article-title":"Analyzing survival curves at a fixed point in time","volume":"26","author":"Klein","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2022.05.020_bib0012","doi-asserted-by":"crossref","first-page":"e13866","DOI":"10.1111\/ctr.13866","article-title":"Clinical \"real-world\" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105106","article-title":"Effective letermovir prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: results from the French temporary authorization of use compassionate program","volume":"148","author":"Beauvais","year":"2022","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jtct.2022.05.020_bib0014","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","article-title":"Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data","volume":"100","author":"Derigs","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.05.020_bib0015","first-page":"1","article-title":"Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide","author":"Freyer","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.05.020_bib0016","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-021-00264-9","article-title":"Impact of letermovir use for cytomegalovirus prophylaxis on re-hospitalization following allogeneic hematopoietic stem cell transplantation: an analysis of a phase III randomized clinical trial","volume":"5","author":"Golan","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jtct.2022.05.020_bib0017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.05.020_bib0018","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.05.020_bib0019","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in cmv-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2022.05.020_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740079","article-title":"Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience","volume":"11","author":"Martino","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.05.020_bib0021","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0022","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.21873\/anticanres.14611","article-title":"Incidence of CMV replication and the role of letermovir primary\/secondary prophylaxis in the early phase after allogeneic hematopoietic stem cell transplantation\u2014a single centre study","volume":"40","author":"Studer","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2022.05.020_bib0023","unstructured":"Su Y, Stern A, Karantoni E, et al. Impact of letermovir primary cytomegalovirus (CMV) prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation (HCT): a retrospective cohort study [e-pub ahead of print January 3, 2022]. Clin Infect Dis. 10.1093\/cid\/ciab1064."},{"key":"10.1016\/j.jtct.2022.05.020_bib0024","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT Study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2022.05.020_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.020_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.05.020_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.020_bib0028","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.020_bib0029","unstructured":"Jamy O, Hebert C, Dunn-Valadez S, et al. Risk of cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation [e-pub ahead of print January 21, 2022]. Transplant Cell Ther. 10.1016\/j.jtct.2022.01.011."},{"key":"10.1016\/j.jtct.2022.05.020_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.05.020_bib0031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.05.020_bib0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jmii.2015.07.011","article-title":"Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:45Z","timestamp":1763003265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722013148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2666636722013148"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}